Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6736 to 6750 of 8904 results

  1. Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

    Discontinued Reference number: GID-TA10764

    Technology appraisal guidance
    Discontinued

  2. Treatments for non-small-cell lung cancer [ID6234]

    Discontinued Reference number: GID-TA11289

    Technology appraisal guidance
    Discontinued

  3. Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]

    In development Reference number: GID-TA11021 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]

    In development Reference number: GID-TA11647 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Botulinum toxin type A for preventing episodic migraine [ID6450]

    In development Reference number: GID-TA11505 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Electrochemotherapy for the treatment of malignant melanoma

    Discontinued Reference number: GID-IP1041

    Interventional procedures guidance
    Discontinued

  7. Extra corporeal membrane oxygenation for acute heart failure in children

    Discontinued Reference number: GID-IP1153

    Interventional procedures guidance
    Discontinued

  8. Intravaginal sling for stress urinary incontinence

    Discontinued Reference number: GID-IP267

    Interventional procedures guidance
    Discontinued

  9. High tibial osteotomy with adjustable magnetic nail insertion for symptomatic medial knee osteoarthritis

    Discontinued Reference number: GID-IPG10142

    Interventional procedures guidance
    Discontinued

  10. Community nursing care settings

    Discontinued Reference number: GID-SGWAVE0700

    Safe staffing guideline
    Discontinued

  11. Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]

    In development Reference number: GID-TA11366 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]

    In development Reference number: GID-TA11627 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Moxetumomab pasudotox for treating hairy-cell leukaemia [ID1142]

    Discontinued Reference number: GID-TA10923

    Technology appraisal guidance
    Discontinued

  14. Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071]

    In development Reference number: GID-TA11634 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Pegcetacoplan for treating geographic atrophy [ID4041]

    In development Reference number: GID-TA11351 Expected publication date: TBC

    Technology appraisal guidance
    In development